Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 117

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 117
---
 of the Exchange Act and the rules and regulations
thereunder, including Regulation M, which may limit the timing of purchases and sales of the Depositary Shares by the selling shareholders
or any other person. We will make copies of this prospectus available to the selling shareholders and have informed them of the need to
deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the
Securities Act).

| 75 |

<div align='center'>EXPENSES OF THE OFFERING</div>

The following table sets forth the expenses
payable by us in connection with the sale and distribution of the securities being registered hereby. All amounts shown, other than the
SEC registration fee, are estimates:

| SEC registration fee    | $ |    936 |
| Printing and engraving  |   |  5,000 |
| Accounting services     |   | 15,000 |
| Legal fees and expenses |   | 50,000 |
| Miscellaneous           |   |  5,000 |
| Total                   | $ | 75,936 |

<div align='center'>LEGAL MATTERS</div>

Certain legal matters in connection with
the validity of the securities offered hereby will passed upon for us by Brown Rudnick LLP, London, United Kingdom. Certain other matters
of U.S. federal law will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., Boston, Massachusetts.

<div align='center'>EXPERTS</div>

The financial statements as of December
31, 2024, and for the year then ended, incorporated by reference into this prospectus and in the registration statement have been so incorporated
in reliance on a report PKF Littlejohn LLP, an independent registered accounting firm, given on authority of said firm as experts in auditing
and accounting. The report on the financial statements for the year ended December 31, 2024 contains an explanatory paragraph regarding
our ability to continue as a going concern.

PKF Littlejohn LLP, London, United Kingdom,
is a member of the Institute of Chartered Accountants in England and Wales.

The financial statements of
Biodexa Pharmaceuticals PLC as of December 31, 2023, and for each of the three years in the period then ended, incorporated by reference
in this prospectus and in the registration statement have been so incorporated in reliance on a report of Forvis